Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $25.8B | $25.1B | $22.6B | $20.5B | $18.4B | $17.1B | $14.4B | $14.9B | $13.6B | $12.4B | $11.3B | $9.9B | $9.7B | $9.0B | $8.7B | $8.3B | $7.3B | $6.7B | $6.7B | $6.0B | $5.4B |
| Bruttoergebnis | $16.8B | $16.1B | $14.0B | $12.5B | $11.0B | $10.7B | $8.8B | $9.4B | $8.6B | $7.9B | $7.2B | $6.4B | $6.2B | $5.9B | $5.8B | $5.5B | $5.0B | $4.5B | $4.5B | $4.1B | $3.5B |
| Bruttomarge % | 65.2% | 64.0% | 61.9% | 61.0% | 59.8% | 62.6% | 61.0% | 63.0% | 63.2% | 63.5% | 64.0% | 64.2% | 64.3% | 65.9% | 66.7% | 66.4% | 68.0% | 67.0% | 67.7% | 68.2% | 65.0% |
| Betriebsergebnis (EBIT) | $5.7B | $4.9B | $5.1B | $4.3B | $3.7B | $3.8B | $3.0B | $3.4B | $3.1B | $2.8B | $2.6B | $2.3B | $2.2B | $2.1B | $1.9B | $2.0B | $1.9B | $1.7B | $1.6B | $1.3B | $1.1B |
| Operative Marge % | 22.0% | 19.5% | 22.4% | 20.9% | 20.2% | 22.0% | 21.1% | 22.8% | 22.8% | 22.2% | 22.8% | 22.6% | 23.0% | 23.3% | 22.1% | 23.7% | 25.3% | 25.6% | 23.1% | 22.1% | 20.8% |
| Jahresüberschuss | $3.7B | $3.2B | $3.0B | $3.2B | $2.4B | $2.0B | $1.6B | $2.1B | $3.6B | $1.0B | $1.6B | $1.4B | $515M | $1.0B | $1.3B | $1.3B | $1.3B | $1.1B | $1.1B | $1.0B | $778M |
| Nettomarge % | 14.4% | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% | 14.5% | 5.3% | 11.2% | 15.0% | 16.2% | 17.4% | 16.5% | 17.1% | 17.0% | 14.4% |
| EBITDA | $6.3B | $6.3B | $4.9B | $5.1B | $4.0B | $3.6B | $3.1B | $3.6B | $3.3B | $3.0B | $2.7B | $2.2B | $1.7B | $1.6B | $2.0B | $2.3B | $2.2B | $2.0B | $2.0B | $1.8B | $1.4B |
| Ergebnis je Aktie (EPS) | $9.65 | $8.49 | $7.76 | $8.25 | $6.17 | $5.22 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 | $3.78 | $1.35 | $2.63 | $3.39 | $3.45 | $3.19 | $2.77 | $2.78 | $2.44 | $1.89 |
| Ausstehende Aktien (Mio.) | 386M | 382M | 386M | 384M | 382M | 382M | 380M | 380M | 380M | 380M | 378M | 381M | 383M | 382M | 383M | 390M | 400M | 399M | 414M | 417M | 411M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für SYK. /companies/us/SYK
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms